Status:
COMPLETED
Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
Ministry of Health, France
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
15-59 years
Phase:
PHASE2
Brief Summary
Several prognostic predictors, including baseline ALL features and response to initial therapy, have been described in adult ALL raising the issue of whether these predictors might be redundant and wh...
Detailed Description
1\) baseline (BL) : WBC30G/L in B-lineage, CNS involvement, MLL-AF4 and E2A-PBX fusions, haploidy/near-triploidy; 2) early response (ER) : corticoresistance after prophase (CsR), chemoresistance at Da...
Eligibility Criteria
Inclusion
- 15-59 years
- acute lymphoblastic leukemia newly diagnosed
- signed written informed consent
Exclusion
- Lymphoblastic lymphoma
- Acute lymphoblastic leukemia 3
- Chronic Myeloid Leukemia acutisation
- Sever organ condition
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
December 1 2008
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00222027
Start Date
November 1 2003
End Date
December 1 2008
Last Update
January 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'Hématologie Clinique, Hôpital Purpan
Toulouse, France, 31059